Deep Lens

The goal of precision medicine is simply to deliver the right cancer treatment to the right patient at the right time. Oncology is the one therapeutic area that strongly supports this goal.

As more cellular treatments become FDA-approved, the need for established cellular therapy programs in the community setting will be crucial to expanding the availability of these novel treatments to patients. Learn more...

Are Cell and Gene Therapy Programs Primed for Community Oncology? Deep Lens' Director of Provider Network Amy Zuchelkowski shares her perspective on bringing cell and gene therapies to community oncology practices.

Are Cell and Gene Therapy Programs Primed for Community Oncology?

Offering cell-based therapy is uncharted territory for many community oncology practices. The treatments are seen as groundbreaking, and many patients desire access. Clinical trials allow for this access to the latest and greatest therapies in addition to close monitoring of care by the entire research team.


https://bit.ly/3N08Idi

Stale historical data is often only the best guess on broad I/E criteria. However, because our Real-Time Feasibility Dashboard integrates EMR and geometric data, we can give you up to date insights on your target patients. Learn more here: https://bit.ly/3Hl16k6

📌 Meet the Deep Lens team at the 2022 ASCO Annual Meeting on June 3 - 7, 2022, the most significant oncology research gathering of the year.

Learn more about the Annual Meeting, attendance registration, and the innovative technology which Deep Lens use to help support the diversity in the clinical research here https://bit.ly/3wFkkx9

identifies and matches patients to precision trials in the narrow window of opportunity through lab-agnostic genomic data ingestion.
Download our brochure to learn more about VIPER technology presented by . 👉https://bit.ly/3NemtoS